Pfizer Corporation

Novo Nordisk A/s

Agouron Pharmaceuticals, Inc.

Noro Nordisk A/s

Pfizer Products Inc.

Anthony Lai Ling

Jesper F Lau

Peter Madsen

Yufeng Hong

Vlad Edward Gregor

Michael Bruno Plewe

Shenghua Shi

Larry Kenneth Truesdale

Ulla Grove Sidelmann

Min Teng

Seiji Nukui

Christian Klarner Sams

Carsten Behrens

Jeffrey Allen Pfefferkorn

Hao Bai

Ru Zhou

Simon Bailey

Dilip Ramakant Bhumralkar

Mingying He

Javier Gonzalez

Jihong Lou

Michael David Johnson

Atsuo Kuki

Dan Kiel

Feng C Bi

Behrend Frederik Lundt

Paul Stuart Humphries

Fengli Guo

Jun Feng

Janos Tibor Kodra

Daljit Singh Dhanoa

Lars Naerum

Eileen Valenzuela Tompkins

Henning Thøgersen

Lotte Bjerre Knudsen

Ranjan Jagath Rajapakse

Richard A Bychowski

Henning Th&oslash;gersen

Kimberly Ann Teston

Christian Sams

Inge Th&oslash;ger Christensen

Josef Vagner

Anker Steen Jøgensen

Inge Thøger Christensen

Tso-sheng Chou

Feng Bi

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.

Benzofuranyl derivatives

The present invention relates to a compound of formula (I):  or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of:  Ring A, ring B, ring C, R, R, R, R, R, L, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

Fused phenyl amido heterocyclic compounds

A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

Glucagon antagonists/inverse agonists

There are disclosed novel neuropeptide Y ligands having the general formula IWherein the symbols W, A, D, R, R, R, Rare further defined in the description. Compounds of formula I are agonists and antagonists of neuropeptide Y, and are therefore useful as regulators.

Neuropeptide-Y ligands

Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.

Non-peptide antagonists of GLP-1 receptor and methods of use

Growing community of inventors

San Diego, CA, United States of America

Anthony Lai Ling